Journal of comparative effectiveness research
-
Randomized Controlled Trial Multicenter Study Comparative Study
An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
To compare the efficacy of intravenous (IV) and subcutaneous (SC) belimumab plus standard therapy in patients with active, autoantibody-positive systemic lupus erythematosus and high disease activity (HDA). ⋯ This indirect treatment comparison provides further evidence of the efficacy of belimumab IV and SC in patients with systemic lupus erythematosus and HDA, compared with standard therapy.